Moderna’s mFlusiva wins FDA approval

What's happened

Moderna has won FDA approval for its mRNA flu vaccine mFlusiva for adults 50–64 and accelerated approval for those 65 and older. The decision follows a contentious review earlier this year, a unanimous advisory panel recommendation in June and political disputes inside US health agencies over mRNA vaccines. Retail availability is expected in coming weeks.

What's behind the headline?

What this approval actually means

• The FDA has given traditional approval for mFlusiva in people aged 50–64 and accelerated approval for those 65 and older. Moderna has agreed to run additional studies in the 65+ group to confirm benefit.

How the vaccine changes the market

• mFlusiva will join existing products from Sanofi, GSK, CSL Seqirus and AstraZeneca and will compete particularly for older adults, who account for the majority of flu hospitalisations and deaths. Analysts expect material revenue only after the 2027 season because Moderna missed the 2026 contracting cycle.

Political and regulatory fallout

• The approval has arrived after public clashes inside the FDA and HHS. Senior agency moves earlier this year blocked and then reopened Moderna’s application; Vinay Prasad’s intervention and later departure, and Health Secretary Robert F. Kennedy Jr.’s scepticism of mRNA technology have politicised the review.

Practical consequences for patients and providers

• mRNA manufacture is faster than egg-based production, so mFlusiva will allow quicker updates to match circulating strains in future seasons. The vaccine caused slightly higher short-term reactions (injection site pain, fever, headache) in trials but showed no major safety issues.

Likely next steps

• Moderna will publish postmarketing data for seniors and complete the required confirmatory trial. The CDC advisory panel that sets federal recommendations remains disrupted by litigation over recent appointments; that will affect how widely the vaccine is recommended and purchased for public programmes.

Forecast

• The shot will increase options for older adults and strengthen Moderna’s long-term vaccine strategy, but uptake and public-health impact will depend on CDC guidance, contracting timelines and whether litigation restores a functioning federal advisory process.

How we got here

Moderna’s mFlusiva (mRNA-1010) has been tested in trials of roughly 40,000 adults and shown about 26–27% greater efficacy versus a standard-dose comparator. The FDA delayed and then reversed early rejection amid public disputes; an advisory committee recommended approval in June and the agency has now authorised the shot for older adults.

Our analysis

The approval narrative is consistent across major outlets but each emphasises different elements. AP News and CNBC focus on the regulatory outcome and the trial data: AP reports that the FDA granted full approval for ages 50–64 and accelerated approval for 65+, citing Moderna’s trial of about 40,000 people that showed roughly 27% fewer cases versus a standard vaccine; CNBC reports the same efficacy figure (26.6%) and highlights commercial forecasts and missed contracting for the 2026 season. Ars Technica and The Independent provide the political and procedural context: Ars Technica details the fraught review process, noting that a then-top FDA official initially blocked the application and that Health Secretary Robert F. Kennedy Jr.’s scepticism of mRNA vaccinations has shaped agency actions; The Independent recounts the earlier refusal to review and the $500m HHS funding pull for mRNA research that intensified industry concern. The New York Post and AP/Independent pieces document expected availability and safety observations: Moderna and regulators reported temporary reactogenicity (fever, injection-site pain, headache) but no major safety signals. Read the AP for the straight regulatory summary and the Ars Technica and Independent pieces for the background on internal FDA disputes and policy decisions that framed the review.

Go deeper

• Will the CDC advisory panel meet soon to recommend mFlusiva for older adults?
• How quickly will mFlusiva reach pharmacies and who will pay for it?

More on these topics

• Robert F. Kennedy Jr. - American politician, environmental lawyer, anti-vaccine activist, and conspiracy theorist (born 1954)

  Robert Francis Kennedy Jr. (born January 17, 1954), also known by his initials RFK Jr., is an American politician, environmental lawyer, author, conspiracy theorist, and anti-vaccine activist serving as the 26th United States secretary of health and human

• United States Centers for Disease Control and Prevention - Public agency

  The Centers for Disease Control and Prevention is a national public health institute in the United States. It is a United States federal agency, under the Department of Health and Human Services, and is headquartered in Atlanta, Georgia.

• United States - Country in North America

  The United States of America, commonly known as the United States or America, is a country mostly located in central North America, between Canada and Mexico.

• Massachusetts - US State

  Massachusetts, officially known as the Commonwealth of Massachusetts, is the most populous state in the New England region of the northeastern United States.

• Cambridge - City in Massachusetts

  Cambridge is a city in Middlesex County, Massachusetts, and part of the Boston metropolitan area as a major suburb of Boston. As of July 2019, it was the fifth most populous city in the state, behind Boston, Worcester, Springfield, and Lowell.

• COVID-19 - Contagious disease caused by SARS-CoV-2

  The COVID-19 pandemic, also known as the coronavirus pandemic, is an ongoing pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. It was first identified in December 2019 in Wuhan, China.

• The Wall Street Journal - Newspaper

  The Wall Street Journal is an American business-focused, English-language international daily newspaper based in New York City, with international editions also available in Chinese and Japanese.

• Moderna - Biotechnology company

  Moderna is an American biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA. It is headquartered in Cambridge, Massachusetts.

• CNN - Television channel

  CNN is an American news-based pay television channel owned by CNN Worldwide, a unit of the WarnerMedia News & Sports division of AT&T's WarnerMedia.

• Associated Press - News agency company

  The Associated Press is an American not-for-profit news agency headquartered in New York City. Founded in 1846, it operates as a cooperative, unincorporated association. Its members are U.S. newspapers and broadcasters.

• Howard Hughes Medical Institute - Foundation

  The Howard Hughes Medical Institute (HHMI) is an American non-profit medical research organization based in Chevy Chase, Maryland. It was founded in 1953, by Howard Hughes who was an American business magnate, investor, record-setting pilot, engineer...

• United States Department of Health and Human Services - Government department

  The United States Department of Health & Human Services, also known as the Health Department, is a cabinet-level executive branch department of the U.S. federal government with the goal of protecting the health of all Americans and providing essential

• Measles - Viral disease affecting humans

  Measles (probably from Middle Dutch or Middle High German masel(e), meaning "blemish, blood blister") is a highly contagious, vaccine-preventable infectious disease caused by measles virus. Other names include morbilli, rubeola, 9-day measles, red measles

• Andrew Wakefield - British physician

  Andrew Jeremy Wakefield is a British anti-vaccine activist, former physician, and discredited academic who was struck off the medical register for his involvement in the Lancet MMR autism fraud, a 1998 study that falsely claimed a link between the measles

• World Health Organization

  The World Health Organization is a specialized agency of the United Nations responsible for international public health. The WHO Constitution, which establishes the agency's governing structure and principles, states its main objective as "the attainment